NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
P/B ratio for NovoCure Limited (NVCR)
P/B ratio as of 2023: 4.38
According to NovoCure Limited's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.38. At the end of 2022 the company had a P/B ratio of 17.40.
P/B ratio history for NovoCure Limited from 2013 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 4.38 |
| 2022 | 17.40 |
| 2021 | 18.92 |
| 2020 | 36.65 |
| 2019 | 37.62 |
| 2018 | 27.39 |
| 2017 | 15.75 |
| 2016 | 4.72 |
| 2015 | 2.71 |
| 2014 | 16.21 |
| 2013 | 9.24 |